5-Fluorouracil
5-Fluorouracil 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Colon Adenocarcinoma、Rectal Adenocarcinoma、Endometrial Cancer、Gastric Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
7 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Merck Sharp & Dohme LLC
- AstraZeneca
- Janssen Research & Development, LLC
- National Cancer Institute (NCI)
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- UNC Lineberger Comprehensive Cancer Center
- Fudan University
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、美国、Brazil、Chile、Czechia、法国、德国、意大利、日本、挪威、Singapore、South Korea
正在招募患者的 5-Fluorouracil 研究
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
II 期招募中中国NCT07165847Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
I 期 / II 期招募中美国BrazilChile中国NCT06780111Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
I 期 / II 期招募中美国NCT06483555Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer
II 期招募中中国NCT06121700Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
II 期招募中中国NCT07806292Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
II 期招募中中国NCT06928584Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
III 期招募中意大利NCT06509126Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU
II 期招募中中国NCT07391618The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
IV 期招募中中国NCT06368063Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
III 期招募中法国NCT04747054Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
II 期招募中中国NCT05671822Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
II 期招募中中国NCT06988956AB122 Platform Study
I 期招募中日本NCT04999761sFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)
II 期招募中美国NCT05332002Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
III 期招募中中国NCT07595276DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
III 期招募中荷兰NCT06275958Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy
I 期 / II 期招募中美国NCT07456852A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
I 期招募中美国加拿大中国法国NCT06131840Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
II 期招募中中国NCT07337460DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
II 期招募中法国NCT06757244Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
II 期招募中中国NCT07106034A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
III 期招募中中国NCT03303495Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
III 期招募中中国NCT06041477PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
II 期招募中中国NCT06788171
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。